AKT1 and cancer: It is likely that active components of SLD act through targets to jointly regulate signaling pathways involved in lipid and atherosclerosis, the PI3K-Akt signaling pathway, immune-related signaling pathways, and pathways in cancer to improve patient outcomes (Figure 7A).